Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis

Arthritis and Rheumatism

Volumn 63, Issue 11, 2011, Pages 3512-3521

  Lambrianides, Anastasia ^a   Turner Stokes, Tabitha ^a   Pericleous, Charis ^a   Ehsanullah, Jasmine ^a   Papadimitraki, Eva ^a   Poulton, Katie ^a   Ioannou, Yiannis ^a   Lawrie, Andrew ^a   MacKie, Ian ^a   Chen, Pojen ^b   Latchman, David ^a   Isenberg, David ^a   Rahman, Anisur ^a   Giles, Ian ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9A; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; PLASMIN; POLYCLONAL ANTIBODY; PROTEIN C; SERINE PROTEINASE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEMOSTASIS; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HEMOSTASIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; SERINE PROTEASES; THROMBOSIS;

EID: 80155152605     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30525     Document Type: Article

References (39)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA,. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109: 422-30. (Pubitemid 46105935)
3. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: a prospective analysis of 500 consecutive patients. Medicine (Baltimore) 1989; 68: 353-65. (Pubitemid 19286655)
4. Lynch A, Marlar R, Murphy J, Davila G, Santos M, Rutledge J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome: a prospective study. Ann Intern Med 1994; 120: 470-5. (Pubitemid 24075224)
5. Cugno M, Cabibbe M, Galli M, Meroni PL, Caccia S, Russo R, et al. Antibodies to tissue-type plasminogen activator (tPA) in patients with antiphospholipid syndrome: evidence of interaction between the antibodies and the catalytic domain of tPA in 2 patients. Blood 2004; 103: 2121-6. (Pubitemid 38326228)
6. 2-glycoprotein I and the homologous catalytic domains of several serine proteases. Arthritis Rheum 2007; 56: 1638-47. (Pubitemid 46764093)
7. Lu CS, Horizon AA, Hwang KK, FitzGerald J, Lin WS, Hahn BH, et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005; 52: 4018-27. (Pubitemid 41798242)
8. Hwang KK, Grossman JM, Visvanathan S, Chukwuocha RU, Woods VL Jr, Le DT, et al. Identification of anti-thrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167: 7192-8. (Pubitemid 33144217)
9. Oosting JD, Derksen RH, Bobbink IW, Hackeng TM, Bouma BN, de Groot PG,. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood 1993; 81: 2618-25. (Pubitemid 23147565)
10. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T,. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8. (Pubitemid 20225005)
11. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7. (Pubitemid 20189625)
12. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 4120-4.
13. Yang CD, Hwang KK, Yan W, Gallagher K, FitzGerald J, Grossman JM, et al. Identification of anti-plasmin antibodies in the antiphospholipid syndrome that inhibit degradation of fibrin. J Immunol 2004; 172: 5765-73. (Pubitemid 38542082)
14. Greaves M, Cohen H, MacHin SJ, Mackie I,. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-15. (Pubitemid 30609746)
15. Loizou S, Mackworth-Young CG, Cofiner C, Walport MJ,. Heterogeneity of binding reactivity to different phospholipids of antibodies from patients with systemic lupus erythematosus (SLE) and with syphilis. Clin Exp Immunol 1990; 80: 171-6. (Pubitemid 20147710)
16. Walsh PN, Ahmad SS,. Proteases in blood clotting. Essays Biochem 2002; 38: 95-111. (Pubitemid 36589197)
17. Yang YH, Chien D, Wu M, FitzGerald J, Grossman JM, Hahn BH, et al. Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. J Immunol 2009; 182: 1674-80.
18. Yang YH, Hwang KK, FitzGerald J, Grossman JM, Taylor M, Hahn BH, et al. Antibodies against the activated coagulation factor X (FXa) in the antiphospholipid syndrome that interfere with the FXa inactivation by antithrombin. J Immunol 2006; 177: 8219-25. (Pubitemid 44846343)
19. Hwang KK, Yang CD, Yan W, Grossman JM, Hahn BH, Chen PP,. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003; 48: 1622-30. (Pubitemid 36682370)
20. Giles I, Pericleous C, Liu X, Ehsanullah J, Clarke L, Brogan P, et al. Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. J Immunol 2009; 182: 4836-43.
21. Giles I, Lambrianides N, Pattni N, Faulkes D, Latchman D, Chen P, et al. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol 2006; 177: 1729-36. (Pubitemid 44092509)
22. Giles I, Lambrianedes N, Latchman D, Chen P, Chuckwuocha R, Isenberg D, et al. The critical role of arginine residues in the binding of human antiphospholipid antibodies to cardiolipin. Arthritis Res Ther 2005; 7: R47-56.
23. Giles I, Haley J, Nagl S, Latchman D, Chen P, Chukwuocha R, et al. Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. Mol Immunol 2003; 40: 49-60. (Pubitemid 36937060)
24. 2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies. Br J Haematol 1999; 105: 102-9. (Pubitemid 29197150)
25. Pierangeli SS, Liu X, Espinola R, Olee T, Zhu M, Harris NE, et al. Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models. Thromb Haemost 2000; 84: 388-95.
26. Mason LJ, Lambrianides A, Haley JD, Manson JJ, Latchman DS, Isenberg DA, et al. Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Res Ther 2005; 7: R971-83.
27. Rahman MA, Kettleborough CA, Latchman DS, Isenberg DA,. Properties of whole human IgG molecules produced by the expression of cloned anti-DNA antibody cDNA in mammalian cells. J Autoimmun 1998; 11: 661-9. (Pubitemid 29016124)
28. Ehrenstein MR, Longhurst CM, Latchman DS, Isenberg DA,. Serological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotype. J Clin Invest 1994; 93: 1787-97. (Pubitemid 24116422)
29. Menon S, Rahman MA, Ravirajan CT, Kandiah D, Longhurst CM, McNally T, et al. The production, binding characteristics and sequence analysis of four human IgG monoclonal antiphospholipid antibodies. J Autoimmun 1997; 10: 43-57. (Pubitemid 27110307)
30. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7. (Pubitemid 13221242)
31. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al, for the Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-27. (Pubitemid 34303815)
32. Vianna JL, Khamashta MA, Ordi-Ros J, Font J, Cervera R, Lopez-Soto A, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European multicenter study of 114 patients. Am J Med 1994; 96: 3-9. (Pubitemid 24043645)
33. Bidot CJ, Jy W, Horstman LL, Huisheng H, Jimenez JJ, Yaniz M, et al. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol 2003; 120: 618-26. (Pubitemid 36255862)
34. Jones DW, Gallimore MJ, MacKie IJ, Harris SL, Winter M,. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol 2000; 110: 721-6.
35. 2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004; 63: 1478-82. (Pubitemid 39433954)
36. Bock PE, Olson ST, Bjork I,. Inactivation of thrombin by antithrombin is accompanied by inactivation of regulatory exosite I. J Biol Chem 1997; 272: 19837-45. (Pubitemid 27340078)
37. Miesbach W, Matthias T, Scharrer I,. Identification of thrombin antibodies in patients with antiphospholipid syndrome. Ann N Y Acad Sci 2005; 1050: 250-6. (Pubitemid 41129442)
38. 2-glycoprotein I on thrombin-mediated factor XIa generation. Arthritis Rheum 2007; 56: 605-13.
39. 2-glycoprotein I autoantibodies. Arthritis Rheum 2008; 58: 1146-55. (Pubitemid 351564018)